Understanding China’s Animal Testing Landscape

Since May 1, 2021, foreign beauty brands have been able to legally avoid animal testing for ordinary cosmetics imported into China under the Cosmetics Supervision and Administration Regulation (CSAR, 化妆品监督管理条例, Huàzhuāngpǐn Jiāndū Guǎnlǐ Tiáolì) — provided they meet 5 specific qualification criteria. This guide explains exactly how to qualify, what documentation is required, and which product categories still require animal testing.

Understanding China’s Animal Testing Landscape

Before 2021, China’s cosmetics regulatory framework under the 1990 Cosmetics Hygiene Supervision Regulation required all imported cosmetics to undergo animal testing at a designated Chinese laboratory before receiving NMPA approval. This testing typically involved dermal irritation tests (rabbit skin), eye irritation tests (rabbit eyes), skin sensitization tests (guinea pigs), and repeat-dose toxicity tests (rats). The enactment of CSAR in January 2021, followed by implementation on May 1, 2021, fundamentally changed this framework. Under the new system, China accepts alternative safety assessment methods — in vitro testing, computer modeling (QSAR), and existing human data — in place of animal testing for ordinary cosmetics.

5 Eligibility Criteria for the Exemption

To qualify for the animal testing exemption, a foreign brand must meet all 5 cumulative conditions:

Criterion 1 — Ordinary cosmetics only: Only ordinary cosmetics (普通化妆品, pǔtōng huàzhuāngpǐn) qualify: moisturizers, cleansers, makeup, body lotions, shampoos, and fragrances. Special cosmetics (sunscreen, whitening, hair dye, anti-hair loss) are generally not eligible.

Criterion 2 — Complete safety assessment dossier: The brand must submit a comprehensive safety assessment report (安全评估报告, ānquán pínggū bàogào) prepared by a qualified toxicologist. This includes: full ingredient safety analysis using existing published data (COSMOS, SCCS, CIR, WHO assessments), formulation stability data, microbiological limit testing results, and a risk assessment for each ingredient at its maximum usage concentration.

Criterion 3 — Chinese responsible person: The foreign brand must appoint a Chinese responsible person (境内责任人, jìngnèi zérènrén) — a legal entity registered in China that assumes full regulatory responsibility. This entity cannot be an individual; it must be a company with cosmetics-distribution-compatible business scope.

Criterion 4 — GMP-certified manufacturing facility: The overseas manufacturing facility must be registered with the NMPA or hold ISO 22716 certification. The facility registration must be updated every 3 years.

Criterion 5 — IECIC-compliant ingredients: The product formulation must comply with the Inventory of Existing Cosmetic Ingredients in China (IECIC, 已使用化妆品原料目录). Any ingredient not listed in IECIC requires a New Cosmetic Ingredient (NCI) registration — a 12 to 24 month process that itself requires animal testing.

Building the Qualified Safety Assessment Dossier

The safety assessment dossier is the most critical document for avoiding animal testing. It must demonstrate, through non-animal methods, that the product is safe for human use.

1. Product information summary: Product name, manufacturer details, country of origin, intended use, target consumer population, maximum daily exposure estimate
2. Ingredient-by-ingredient safety analysis: For each ingredient: INCI name, CAS number, function, maximum concentration, safety conclusion from authoritative sources (SCCS, CIR, WHO)
3. Formulation stability testing: Accelerated (40°C/75% RH for 3 months) and long-term (25°C/60% RH for 24 months) from a CNAS-accredited lab
4. Microbiological limit testing: TAMC ≤ 100 CFU/g (Category 1) or ≤ 500 CFU/g (Category 2) per GB/T 35829-2018
5. Heavy metal screening: Lead ≤ 10 ppm, arsenic ≤ 2 ppm, mercury ≤ 1 ppm, cadmium ≤ 5 ppm via ICP-MS
6. Risk assessment conclusion: Margin of Safety (MoS) = NOAEL / SED. MoS ≥ 100 is acceptable. MoS < 100 means animal testing is required.
7. Assessor qualification statement: Name, professional qualifications, and signature of the safety assessor — degree in toxicology or related field with 3+ years of cosmetic safety assessment experience

Common Mistakes in Margin of Safety (MoS) Calculations

The Margin of Safety (MoS) calculation is the single most scrutinized component of any safety assessment dossier submitted under the CSAR animal-testing exemption. A miscalculated MoS is the leading cause of filing rejections by the NMPA. Below are the most frequently encountered errors and how to avoid them.

Incorrect No-Observed-Adverse-Effect-Level (NOAEL) selection. The NOAEL must be derived from the most relevant study route — dermal exposure for leave-on cosmetics, oral only when dermal data is unavailable. A common error is using an oral NOAEL without applying the appropriate dermal absorption correction factor. For example, using a rat oral NOAEL of 100 mg/kg/day from a 90-day feeding study directly in an MoS calculation for a face cream will produce an inflated (false positive) MoS. The NMPA expects the NOAEL to be adjusted by a dermal absorption fraction (typically 10–50% depending on the ingredient and vehicle). Brands that skip this step routinely see their files returned for revision.

Underestimating Systemic Exposure Dose (SED). The SED must account for the maximum realistic exposure scenario, not an average. For a body lotion, this means assuming application to 100% of body surface area (approximately 1.8 m² for an adult) at the maximum recommended frequency (e.g., twice daily). Many brands calculate SED based on a single application or a reduced body surface area, which produces an artificially low SED and an inflated MoS. The NMPA’s 2023 Safety Assessment Technical Guidelines explicitly require worst-case exposure assumptions. A face serum must assume 2 g/day application to an 800 cm² facial area, not 0.5 g/day. Underestimating by even 1 g/day can change the MoS from 120 (pass) to 85 (fail).

Aggregating exposure from multiple products. The NMPA expects cumulative exposure calculations when a single ingredient appears in multiple product categories (e.g., a consumer using both a moisturizer and a serum containing the same preservative). Many brands calculate MoS for each product in isolation, ignoring aggregate exposure. For preservatives such as phenoxyethanol or parabens that appear across product lines, the cumulative SED can exceed the acceptable daily intake even when each individual product passes. The NMPA guidance recommends an aggregate exposure factor of 1.5× to 3× for overlapping product use. Failing to aggregate is the most common rejection reason for multi-product filings.

Incorrect NOAEL unit conversion. International safety data often reports NOAEL values in parts per million (ppm) in diet or mg/kg feed, not mg/kg body weight per day. Conversion errors — particularly between mg/kg feed and mg/kg bw/day using incorrect feed consumption assumptions — are a frequent source of mistakes. The standard rat feed consumption is approximately 0.05 kg feed per kg body weight per day; for dogs it is 0.025 kg feed per kg body weight per day. Using the wrong conversion factor can shift the NOAEL by a factor of 2–3. Always double-check units against the original study source and document the conversion methodology explicitly in the dossier.

Using a NOAEL without an uncertainty factor adjustment for study duration. If the NOAEL is derived from a subchronic (90-day) study but the product is intended for chronic use (365+ days), the NMPA expects an additional uncertainty factor of 2× to 3× applied to account for the duration extrapolation. For leave-on products such as moisturizers and anti-aging creams that are used daily for years, this adjustment is mandatory. Many brands incorrectly apply subchronic NOAEL values without this factor, resulting in an MoS that meets the 100 threshold on paper but fails regulatory review. Apply a default factor of 3× for subchronic-to-chronic extrapolation unless a valid scientific justification for a lower factor is provided.

Failure to account for special population sub-groups. Products targeted at or likely to be used by pregnant women, children under 12, or individuals with compromised skin barriers require additional safety factors. The children’s cosmetics regulations (2022) mandate an MoS ≥ 200 for products intended for children under 3 years. Even for general-market products, if the exposure modeling shows significant use by sensitive populations, an additional safety factor (typically 2× to 5×) must be applied. Ignoring pediatric or pregnancy exposure scenarios is a specific finding flagged by NMPA inspectors during dossier review.

Documentation of the MoS calculation process. Every MoS calculation must include a clear audit trail: the source of the NOAEL (with reference to the original published study or authoritative review), the dermal absorption rate used (justified by data from published studies or in vitro skin permeability tests), all conversion factors applied, the complete SED calculation with all assumptions listed, and the final MoS value. Incomplete documentation — for instance, stating “MoS = 250” without showing the intermediate steps — is grounds for rejection. The NMPA’s 2024 enforcement notice specifically cited incomplete MoS documentation as the top deficiency in filed safety assessment reports, accounting for 34% of all rejection notices issued during the year. Using a standardized MoS calculation template from a qualified third-party consultant significantly reduces this risk.

Products That Still Require Animal Testing

Despite the CSAR reforms, several categories remain subject to mandatory animal testing. Special cosmetics (特殊化妆品) — sunscreens, whitening products, hair dyes, anti-hair loss products, and depigmentation products — must undergo NMPA registration with full animal testing per CSAR Article 16. The NMPA has indicated that alternative methods may be accepted in the future, but as of July 2026 no formal exemption has been issued.

New Cosmetic Ingredients (NCI) not listed in the IECIC require NCI registration. Per CSAR Article 11, NCI registration includes a full toxicological evaluation mandating animal testing — unless the ingredient is food-grade, has FDA GRAS status, or has an established safe history in comparable regulatory systems. Children’s cosmetics face stricter standards under the Children’s Cosmetics Supervision and Administration Regulations (2022) — while ordinary children’s products can theoretically qualify for the exemption, regulators apply a stricter standard and many brands still opt for animal testing for first-time entries.

• High-risk formulations: Products with nanoparticles, penetration enhancers, or systemic absorption potential face case-by-case review and may require animal data
• Novel delivery systems: Liposomes, ethosomes, or other technologies lacking established safety data in China are presumed to require testing
• First-time brands from new source countries: Face more rigorous regulatory review that can effectively require additional testing

Cross-Border E-Commerce as an Alternative

For brands that cannot meet the CSAR exemption criteria or whose products are special cosmetics, the cross-border e-commerce (跨境电商, kuàjìng diànshāng) channel offers a complete workaround. Under the Cross-Border Direct Import Channel (CBDIC), imported cosmetics are classified as personal-use items — not commercial imports — and therefore fall outside the NMPA’s cosmetics regulatory framework entirely. No NMPA filing, no registration, and no animal testing is required.

The key limitations of CBDIC are: per-transaction cap of RMB 5,000, annual per-person cap of RMB 26,000, and the inability to sell through domestic retail channels. Despite these restrictions, cross-border beauty imports reached USD 8.3 billion in 2025 — approximately 18% of China’s total beauty e-commerce market.

Cost-Benefit Analysis of Compliance Routes

Choosing the right market entry route is a strategic decision that depends on product type, budget, timeline, and channel ambitions. Below is a detailed cost-benefit comparison of the three primary routes — CSAR exemption (animal-testing-free filing), CBDIC cross-border e-commerce, and full NMPA registration with animal testing — based on 2026 market data.

When to choose the CSAR exemption: This route is ideal for established brands with 5+ products that already have complete safety data packages. The upfront investment of USD 18,000–35,000 per product is recouped through full domestic channel access — Tmall Supermarket, JD.com, offline retail counters, and Sephora China. Brands with 10 or more products should negotiate a volume discount with their safety assessment consultant, potentially reducing per-product costs to USD 10,000–15,000. The breakeven point versus CBDIC is typically reached at 18–24 months, after which the CSAR exemption route becomes more cost-effective due to higher domestic revenue potential.

When to choose CBDIC: This is the fastest and lowest-risk route, ideal for early-stage brands, small catalogs (1–5 products), or special cosmetics that cannot qualify for the exemption. The total upfront cost of USD 3,000–8,000 is accessible for most independent brands. However, the annual per-person cap of RMB 26,000 (~USD 3,600) limits large-scale growth — a brand generating 5,000 repeat customers spending RMB 5,000/year each would hit a USD 18 million revenue ceiling under the current cap. CBDIC should be viewed as a market validation tool: test consumer response for 6–12 months, then transition high-performing products to the CSAR exemption route for full market access.

When to choose full NMPA registration: Necessary for special cosmetics (sunscreen, whitening, hair dye) and ordinary cosmetics with novel ingredients not on the IECIC. The total cost of USD 50,000–95,000 per product makes this a significant investment that should be reserved for hero products with proven demand. Brands launching in this category should budget for a 12-month timeline and factor in the reputational cost of animal testing — some brands mitigate this through carbon-offset programs and transparent communication about regulatory constraints. Multi-product registrations benefit from shared toxicology study costs; the marginal cost per additional product drops to approximately USD 20,000–35,000.

International Certifications That Support the Exemption

While the CSAR animal-testing exemption is a regulatory determination made by the NMPA based on a product’s safety dossier, holding internationally recognized certifications strengthens a filing in several important ways. These certifications serve as independent, third-party verification of manufacturing quality, product safety, and regulatory compliance — all of which contribute to a favorable review outcome.

ISO 22716 — Cosmetics Good Manufacturing Practices (GMP). ISO 22716 (Cosmetics — Good Manufacturing Practices) is the international standard for cosmetics manufacturing quality management. The NMPA explicitly recognizes ISO 22716 certification as meeting Criterion 4 of the animal-testing exemption (GMP-certified manufacturing facility). A manufacturing facility holding ISO 22716 certification satisfies the facility registration requirement without additional NMPA on-site inspection. The certification process involves: (1) a gap analysis of existing production processes against ISO 22716 requirements (typical cost: USD 3,000–5,000), (2) implementation of corrective actions including documentation of standard operating procedures, batch records, hygiene controls, water quality monitoring, and complaint handling (cost: USD 8,000–20,000 depending on facility size), (3) internal audit and management review, and (4) certification audit by an accredited third-party certifying body such as SGS, Bureau Veritas, or TÜV Rheinland (audit cost: USD 5,000–10,000). The certification is valid for 3 years with annual surveillance audits (USD 2,000–3,000 per year). Total first-cycle cost: USD 16,000–35,000. Benefits for the CSAR filing: automatic satisfaction of Criterion 4, faster NMPA processing time (anecdotal evidence suggests 2–4 weeks faster than facilities without certification), and higher credibility during post-market sampling inspections. The NMPA’s 2024 annual report noted that 94% of products filed under the exemption from ISO 22716-certified facilities passed the first review cycle, compared to 72% from non-certified facilities.

GMPC — Good Manufacturing Practices for Cosmetics (US & ASEAN). GMPC (Good Manufacturing Practices for Cosmetics) is a certification standard developed by the US FDA and adopted by the ASEAN cosmetics directive. While not identical to ISO 22716, GMPC certification covers substantially equivalent requirements: quality management system, personnel hygiene and training, premises and equipment maintenance, raw material control, production and in-process control, finished product testing, and recall procedures. The NMPA accepts GMPC certification as prima facie evidence of a compliant manufacturing facility under Criterion 4, though it may request supplementary documentation showing equivalence to ISO 22716. GMPC certification is particularly advantageous for brands manufacturing in Southeast Asia or the United States where this standard is more prevalent than ISO 22716. Certification cost: USD 10,000–18,000 (first cycle), with annual renewal audits. For US-based manufacturers, holding both GMPC and FDA registration creates the strongest possible quality assurance profile for NMPA review.

FDA Cosmetic Facility Registration (US). The US FDA’s Voluntary Cosmetic Registration Program (VCRP), while not a certification per se, provides an independent government record of a manufacturing facility’s compliance with US federal cosmetics regulations. Under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), facility registration became mandatory for US manufacturers effective December 2024. For foreign brands exporting to China, FDA registration serves as a powerful supplementary document demonstrating that the facility operates under a rigorous regulatory framework equivalent to China’s requirements. The NMPA has historically viewed FDA-registered facilities favorably during the exemption review process — the FDA registration number, combined with a statement of compliance with 21 CFR Part 700 (cosmetics regulations) and Part 701 (labeling), can substitute for portions of the facility documentation required in the safety assessment dossier. Registration cost: USD 0 (FDA does not charge a fee; third-party consultants charge USD 500–1,500 for filing assistance). The key benefit is regulatory credibility: FDA-registered facilities face a substantially lower rate of documentation requests during NMPA filing review. In 2025, the NMPA accepted over 1,200 filings from FDA-registered facilities, with a first-pass approval rate of 89% versus 71% for facilities without comparable international regulatory oversight.

Synergistic certification strategy. Brands seeking the strongest possible position should pursue a multi-certification approach: ISO 22716 as the primary certification (directly recognized by NMPA under Criterion 4), supplemented by applicable regional standards (GMPC for US/ASEAN facilities, ASEAN Cosmetic GMP for Southeast Asian production) and FDA facility registration (for US manufacturers). The combined certification package signals to NMPA reviewers that the manufacturing operation meets multiple rigorous international standards, reducing the likelihood of follow-up inquiries. Certification synergy also provides a fallback: if ISO 22716 certification is delayed, GMPC certification with an equivalence statement can bridge the gap during the filing period. The total cost of a combined certification program ranges from USD 20,000–45,000 for the first cycle, with annual maintenance costs of USD 4,000–8,000 — a small fraction of the cost of a single rejected filing.

Post-Market Surveillance and Labeling

Even brands qualifying for the exemption must comply with post-market rules. Under CSAR Article 34, all cosmetics sold in China must bear a Chinese-language label including: product name, manufacturer, batch number, net content, ingredient list (INCI in Chinese), production date and shelf life, NMPA filing number, and the Chinese responsible person’s details. Ordinary cosmetics display a filing number format: 国妆网备进字(YYYY)第XXXX号. Products sold through CBDIC display: “跨境商品 (个人购买, 不得转售)”.

Post-market surveillance under CSAR Article 57 requires the Chinese responsible person to report adverse events within 24 hours (serious) or 30 days (non-serious). Failure results in filing revocation and fines. The NMPA conducts random sampling on approximately 2% of filed products annually — if safety data is found inadequate, the filing is revoked and the product must be removed within 30 days.

Where to Go From Here

Based on what you just read:

• Ready to act? Read [guide: SLUG-TO-BE-FILLED]
• Still comparing? See [comparison: SLUG-TO-BE-FILLED]
• Need numbers? Try [tool: SLUG-TO-BE-FILLED]

How to Avoid Animal Testing for Cosmetics in China — first published on China Gateway 360. Last updated: July 2026.